Ocata Therapeutics, Inc.
 (OCAT)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Nov. 9, 2015, 10:17 AM
    • Ocata Therapeutics (OCAT -8.8%) Q3 results: Revenues: $84.3K (+113.4%); R&D Expense: $4.3M (+79.2%); SG&A: $3.1M (+93.8%); Operating Loss: ($7.4M) (-85.0%); Net Loss: ($3.8M) (+13.6%); Loss Per Share: ($0.09) (+30.8%); Quick Assets: $32.1M (+629.5%).
    • No guidance given.
    | Nov. 9, 2015, 10:17 AM
  • Nov. 9, 2015, 9:17 AM
    • Ocata Therapeutics (NASDAQ:OCAT): Q3 EPS of -$0.09 beats by $0.09.
    • Revenue of $0.08M (+100.0% Y/Y)
    • Shares -9.5% PM.
    • 10Q
    | Nov. 9, 2015, 9:17 AM | 4 Comments
  • Aug. 6, 2015, 4:26 PM
    • Ocata Therapeutics (NASDAQ:OCAT): Q2 EPS of -$0.20 misses by $0.01.
    | Aug. 6, 2015, 4:26 PM | 1 Comment
  • Nov. 7, 2014, 9:39 AM
    • Advanced Cell Technology (OTCQB:ACTC) will report Q3 results on November 10 after the close. The conference call will begin at 4:30 pm ET.
    | Nov. 7, 2014, 9:39 AM
Company Description
Ocata Therapeutics Inc is a clinical stage biotechnology company in development & commercialization of Regenerative Ophthalmology therapeutics for Stargardt's macular degeneration, dry age-related macular degeneration, & myopic macular degeneration.